export interface DrugApproval {
  approvalMonth: string;
  approvalDate: string;
  ndaBlaNumber: string;
  applicationNo: string;
  applicationType: string;
  brandName: string;
  activeIngredient: string;
  sponsor: string;
  indicationFull: string;
  therapeuticArea: string;
  isOncology: boolean;
  isBiosimilar: boolean;
  isNovelDrug: boolean;
  isOrphanDrug: boolean;
  isCberProduct?: boolean; // CBER-regulated product (tissue, cellular/gene therapy) - not in Drugs@FDA
  approvalType: string;
  supplementCategory?: string; // Supplement Categories or Approval Type
  notes: string;
  fdaUrl?: string;
}

export const fdaApprovals: DrugApproval[] = [
  // ===== 2025년 12월 승인 (오름차순) =====
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-03",
    ndaBlaNumber: "BLA 761544",
    applicationNo: "761544",
    applicationType: "BLA",
    brandName: "AVANCE",
    activeIngredient: "acellular nerve allograft-arwx",
    sponsor: "Axogen",
    indicationFull: "말초신경 복구를 위한 무세포 신경 동종이식",
    therapeuticArea: "신경과 - 신경복구",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    isCberProduct: true, // Tissue product - CBER regulated
    approvalType: "정규승인",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA 최초 승인 무세포 신경 동종이식",
    fdaUrl: "https://www.fda.gov/vaccines-blood-biologics/tissue-tissue-products/avance-nerve-graft",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-05",
    // Note: BLA 125486 corresponds to GAZYVA. BREYANZI is under BLA 125714.
    ndaBlaNumber: "BLA 125714",
    applicationNo: "125714",
    applicationType: "BLA",
    brandName: "BREYANZI",
    activeIngredient: "lisocabtagene maraleucel",
    sponsor: "Bristol Myers Squibb",
    indicationFull: "이전에 최소 2회 이상의 전신 치료를 받은 재발성 또는 불응성 변연부 림프종(MZL) 성인 환자 치료",
    therapeuticArea: "항암제 - 림프종",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Efficacy (New Indication)",
    notes: "변경승인 - 변연부 림프종 적응증 확대",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lisocabtagene-maraleucel-relapsed-or-refractory-marginal-zone-lymphoma",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-09",
    ndaBlaNumber: "BLA 125832",
    applicationNo: "125832",
    applicationType: "BLA",
    brandName: "WASKYRA",
    activeIngredient: "beremagene geparvorepvec",
    sponsor: "Sobi",
    indicationFull: "Wiskott-Aldrich 증후군 소아 환자의 유전자 치료",
    therapeuticArea: "면역학 - 유전자치료",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: true,
    isCberProduct: true, // Gene therapy - CBER regulated
    approvalType: "정규승인",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA 최초 승인 WAS 유전자 치료",
    fdaUrl: "https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/waskyra-beremagene-geparvorepvec",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-11",
    ndaBlaNumber: "BLA 761145",
    applicationNo: "761145",
    applicationType: "BLA",
    brandName: "DARZALEX FASPRO",
    activeIngredient: "daratumumab and hyaluronidase-fihj",
    sponsor: "Janssen Biotech",
    indicationFull: "고위험 무증상 다발골수종 성인 환자의 단독요법 치료",
    therapeuticArea: "항암제 - 다발골수종",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Efficacy (New Indication)",
    notes: "변경승인 - 무증상 다발골수종 신규 적응증",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-high-risk-smoldering-multiple-myeloma",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-11",
    ndaBlaNumber: "NDA 219884",
    applicationNo: "219884",
    applicationType: "NDA",
    brandName: "DAYBUE STIX",
    activeIngredient: "trofinetide",
    sponsor: "Acadia Pharmaceuticals",
    indicationFull: "레트 증후군 성인 및 소아 환자 치료를 위한 새로운 제형",
    therapeuticArea: "신경과 - 레트증후군",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "Type 3 - New Dosage Form",
    notes: "새로운 제형 (New Dosage Form) 승인 - 스틱 포장",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219884",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-11",
    ndaBlaNumber: "NDA 219776",
    applicationNo: "219776",
    applicationType: "NDA",
    brandName: "ORLADEYO",
    activeIngredient: "berotralstat dihydrochloride",
    sponsor: "BioCryst",
    indicationFull: "유전성 혈관부종 예방을 위한 새로운 제형",
    therapeuticArea: "면역학 - 혈관부종",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "Type 3 - New Dosage Form",
    notes: "새로운 제형 (New Dosage Form) 승인",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219776",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-12",
    ndaBlaNumber: "NDA 216793",
    applicationNo: "216793",
    applicationType: "NDA",
    brandName: "AKEEGA",
    activeIngredient: "niraparib and abiraterone acetate",
    sponsor: "Janssen Biotech",
    indicationFull: "BRCA2 변이 전이성 거세민감성 전립선암(mCSPC) 성인 환자 치료를 위한 프레드니손 병용요법",
    therapeuticArea: "항암제 - 전립선암",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Efficacy (New Indication)",
    notes: "거세민감성 전립선암 최초 PARP 억제제",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca2-mutated-metastatic-castration",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-12",
    ndaBlaNumber: "NDA 218571",
    applicationNo: "218571",
    applicationType: "NDA",
    brandName: "CARDAMYST",
    activeIngredient: "etripamil",
    sponsor: "Milestone Pharmaceuticals",
    indicationFull: "성인 발작성 상심실성 빈맥(PSVT) 치료를 위한 비강 스프레이",
    therapeuticArea: "심장내과 - 부정맥",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA 최초 승인 PSVT 비강 스프레이",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-type-abnormally-fast-heart-rhythm",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-12",
    ndaBlaNumber: "NDA 219491",
    applicationNo: "219491",
    applicationType: "NDA",
    brandName: "NUZOLVENCE",
    activeIngredient: "zoliflodacin",
    sponsor: "Qpex Biopharma",
    indicationFull: "성인 임질 치료를 위한 경구용 항생제",
    therapeuticArea: "감염내과 - 성매개감염병",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA 최초 승인 spiropyrimidinetrione 계열 항생제",
    fdaUrl: "https://www.fda.gov/news-events/press-announcements/fda-approves-two-oral-therapies-treat-gonorrhea",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-12",
    ndaBlaNumber: "BLA 761427",
    applicationNo: "761427",
    applicationType: "BLA",
    brandName: "LEROCHOL",
    activeIngredient: "lerodalcibep-liga",
    sponsor: "LIB Therapeutics",
    indicationFull: "이형접합 가족성 고콜레스테롤혈증 또는 동맥경화성 심혈관질환 환자의 LDL-C 감소",
    therapeuticArea: "심장내과 - 고콜레스테롤",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA 최초 승인 PCSK9 억제 융합단백질",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-new-medicine-lowering-cholesterol",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-16",
    ndaBlaNumber: "BLA 761458",
    applicationNo: "761458",
    applicationType: "BLA",
    brandName: "EXDENSUR",
    activeIngredient: "depemokimab-ulaa",
    sponsor: "GSK",
    indicationFull: "호산구 표현형 중증 천식 성인 환자 치료를 위한 장기작용 IL-5 길항제",
    therapeuticArea: "호흡기내과 - 천식",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA 최초 승인 장기작용 IL-5 길항제",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-maintenance-treatment-severe-asthma",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-16",
    ndaBlaNumber: "NDA 210858",
    applicationNo: "210858",
    applicationType: "NDA",
    brandName: "VYBRIQUEDA",
    activeIngredient: "sildenafil citrate",
    sponsor: "IBSA",
    indicationFull: "발기부전 치료를 위한 새로운 제형",
    therapeuticArea: "비뇨기과 - 발기부전",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "Type 3 - New Dosage Form",
    notes: "새로운 제형 (New Dosage Form) 승인",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210858",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-17",
    ndaBlaNumber: "BLA 761139",
    applicationNo: "761139",
    applicationType: "BLA",
    brandName: "ENHERTU",
    activeIngredient: "fam-trastuzumab deruxtecan-nxki",
    sponsor: "Daiichi Sankyo/AstraZeneca",
    indicationFull: "HER2 양성 절제불가능 또는 전이성 유방암 성인 환자의 1차 치료를 위한 pertuzumab 병용요법",
    therapeuticArea: "항암제 - 유방암",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Efficacy (New Indication)",
    notes: "변경승인 - pertuzumab 병용 1차 치료",
    fdaUrl: "https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-fam-trastuzumab-deruxtecan-nxki-pertuzumab-unresectable-or-metastatic-her2-positive",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-17",
    ndaBlaNumber: "BLA 761433",
    applicationNo: "761433",
    applicationType: "BLA",
    brandName: "RYBREVANT FASPRO",
    activeIngredient: "amivantamab and hyaluronidase-lpuj",
    sponsor: "Johnson & Johnson",
    indicationFull: "EGFR 변이 비소세포폐암 성인 환자의 피하주사 제형 치료",
    therapeuticArea: "항암제 - 폐암",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - New Dosage Form",
    notes: "변경승인 - 피하주사 제형 추가",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-amivantamab-and-hyaluronidase-lpuj-subcutaneous-injection/",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-18",
    ndaBlaNumber: "BLA 761473",
    applicationNo: "761473",
    applicationType: "BLA",
    brandName: "NUFYMCO",
    activeIngredient: "ranibizumab-leyk",
    sponsor: "Formycon",
    indicationFull: "황반변성, 황반부종, 당뇨망막병증, 근시성 맥락막신생혈관 치료",
    therapeuticArea: "안과",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "BLA - Biosimilar",
    notes: "Lucentis (ranibizumab) 상호교환가능 바이오시밀러",
    fdaUrl: "https://www.fda.gov/drugs/biosimilars/fda-approves-ranibizumab-leyk-interchangeable-biosimilar-lucentis",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-19",
    ndaBlaNumber: "NDA 209115",
    applicationNo: "209115",
    applicationType: "NDA",
    brandName: "RUBRACA",
    activeIngredient: "rucaparib",
    sponsor: "Clovis Oncology",
    indicationFull: "BRCA 변이 전이성 거세저항성 전립선암(mCRPC) 성인 환자 치료",
    therapeuticArea: "항암제 - 전립선암",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Efficacy (New Indication)",
    notes: "변경승인 - mCRPC 적응증 추가 (신속승인→정규승인 전환)",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-regular-approval-rucaparib-metastatic-castration-resistant-prostate-cancer",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-19",
    ndaBlaNumber: "BLA 761457",
    applicationNo: "761457",
    applicationType: "BLA",
    brandName: "OZILTUS",
    activeIngredient: "denosumab-mobz",
    sponsor: "Amneal Pharmaceuticals",
    indicationFull: "다발골수종 또는 고형암 골전이 환자의 골격 관련 사건 예방, 골거대세포종 치료, 악성종양 고칼슘혈증 치료",
    therapeuticArea: "항암제 - 골전이",
    isOncology: true,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "BLA - Biosimilar",
    notes: "Xgeva (denosumab) 바이오시밀러",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-denosumab-mobz-biosimilar-xgeva",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-19",
    ndaBlaNumber: "NDA 219083",
    applicationNo: "219083",
    applicationType: "NDA",
    brandName: "MYQORZO",
    activeIngredient: "aficamten",
    sponsor: "Cytokinetics",
    indicationFull: "증상이 있는 폐쇄성 비대성 심근병증 성인 환자의 기능적 능력 및 증상 개선",
    therapeuticArea: "심장내과 - 심근병증",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA 최초 승인 심근 억제제",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-improve-functional-capacity-and-symptoms-adults-rare-inherited-heart-condition",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-19",
    ndaBlaNumber: "BLA 761456",
    applicationNo: "761456",
    applicationType: "BLA",
    brandName: "BONCRESA",
    activeIngredient: "denosumab-mobz",
    sponsor: "Amneal Pharmaceuticals",
    indicationFull: "골다공증, 골량감소, 골절위험 증가 환자 치료",
    therapeuticArea: "내분비내과 - 골다공증",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "BLA - Biosimilar",
    notes: "Prolia (denosumab) 바이오시밀러",
    fdaUrl: "https://www.fda.gov/drugs/biosimilars/fda-approves-denosumab-mobz-biosimilar-prolia",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-19",
    ndaBlaNumber: "NDA 220449",
    applicationNo: "220449",
    applicationType: "NDA",
    brandName: "JASCAYD",
    activeIngredient: "nerandomilast",
    sponsor: "Boehringer Ingelheim",
    indicationFull: "특발성 폐섬유증 성인 환자 치료",
    therapeuticArea: "호흡기내과 - 폐섬유증",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "신규 적응증으로 통합 NDA 승인",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220449",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-22",
    ndaBlaNumber: "BLA 761263",
    applicationNo: "761263",
    applicationType: "BLA",
    brandName: "LUNSUMIO VELO",
    activeIngredient: "mosunetuzumab-axgb",
    sponsor: "Genentech",
    indicationFull: "재발성 또는 불응성 여포성 림프종 성인 환자의 피하주사 제형 치료",
    therapeuticArea: "항암제 - 림프종",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - New Dosage Form",
    notes: "변경승인 - 피하주사 제형 추가",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-mosunetuzumab-axgb-subcutaneous-relapsed-or-refractory-follicular-lymphoma",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-22",
    ndaBlaNumber: "NDA 218316",
    applicationNo: "218316",
    applicationType: "NDA",
    brandName: "WEGOVY",
    activeIngredient: "semaglutide",
    sponsor: "Novo Nordisk",
    indicationFull: "비만 또는 과체중 성인 및 청소년의 체중 관리를 위한 새로운 제형",
    therapeuticArea: "내분비내과 - 비만",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "Type 3 - New Dosage Form",
    notes: "새로운 제형 (New Dosage Form) 승인",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218316",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-22",
    ndaBlaNumber: "NDA 217338",
    applicationNo: "217338",
    applicationType: "NDA",
    brandName: "MUCINEX 12HR COLD & FEVER",
    activeIngredient: "dextromethorphan; guaifenesin; naproxen sodium",
    sponsor: "RB Health",
    indicationFull: "감기 및 발열 증상 완화를 위한 복합제",
    therapeuticArea: "호흡기내과 - 감기",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "Type 4 - New Combination",
    notes: "새로운 복합제 (New Combination) 승인",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217338",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-23",
    ndaBlaNumber: "NDA 216196",
    applicationNo: "216196",
    applicationType: "NDA",
    brandName: "AQVESME",
    activeIngredient: "mitapivat",
    sponsor: "Agios Pharmaceuticals",
    indicationFull: "알파-지중해빈혈 또는 베타-지중해빈혈 성인 환자의 빈혈 치료",
    therapeuticArea: "혈액내과 - 지중해빈혈",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Efficacy (New Indication)",
    notes: "변경승인 - 지중해빈혈 적응증 추가",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-oral-treatment-anemia-thalassemia-inherited-blood-disorder",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-23",
    ndaBlaNumber: "BLA 761152",
    applicationNo: "761152",
    applicationType: "BLA",
    brandName: "YARTEMLEA",
    activeIngredient: "narsoplimab-wuug",
    sponsor: "Omeros Corporation",
    indicationFull: "조혈모세포이식 관련 혈전성미세혈관병증 2세 이상 소아 및 성인 환자 치료",
    therapeuticArea: "혈액내과 - TA-TMA",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA 최초 승인 MASP-2 억제제, Breakthrough Therapy 및 Orphan Drug 지정",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-drug-treat-serious-complication-stem-cell-transplant",
  },
  {
    approvalMonth: "2025-12",
    approvalDate: "2025-12-30",
    ndaBlaNumber: "NDA 220152",
    applicationNo: "220152",
    applicationType: "NDA",
    brandName: "NEREUS",
    activeIngredient: "tradipitant",
    sponsor: "Vanda Pharmaceuticals",
    indicationFull: "성인 멀미 예방",
    therapeuticArea: "신경과 - 멀미",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "FDA 최초 승인 NK-1 수용체 길항제 (멀미 적응증)",
    fdaUrl: "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-tradipitant-prevention-motion-sickness-adults",
  },
  // ===== 2026년 1월 승인 (오름차순) =====
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-06",
    ndaBlaNumber: "NDA 213026",
    applicationNo: "213026",
    applicationType: "NDA",
    brandName: "AMONDYS 45",
    activeIngredient: "casimersen",
    sponsor: "Sarepta Therapeutics",
    indicationFull: "듀센 근이영양증 환자의 엑손 45 스키핑 치료",
    therapeuticArea: "신경과 - 근이영양증",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Efficacy",
    notes: "변경승인. 희귀의약품",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213026",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-07",
    ndaBlaNumber: "BLA 761406",
    applicationNo: "761406",
    applicationType: "BLA",
    brandName: "YESINTEK",
    activeIngredient: "ustekinumab-ttwe",
    sponsor: "Biocon Biologics",
    indicationFull: "건선, 건선성 관절염, 크론병, 궤양성 대장염 치료",
    therapeuticArea: "류마티스 - 자가면역질환",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Biosimilar",
    notes: "변경승인. Interleukin-12 Antagonists",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761406",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-08",
    ndaBlaNumber: "NDA 218171",
    applicationNo: "218171",
    applicationType: "NDA",
    brandName: "ENSACOVE",
    activeIngredient: "ensartinib",
    sponsor: "Xcovery",
    indicationFull: "ALK 양성 비소세포폐암 치료",
    therapeuticArea: "항암제 - 폐암",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Efficacy",
    notes: "변경승인",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218171",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-09",
    ndaBlaNumber: "NDA 208411",
    applicationNo: "208411",
    applicationType: "NDA",
    brandName: "NARCAN",
    activeIngredient: "naloxone hydrochloride",
    sponsor: "Emergent BioSolutions",
    indicationFull: "오피오이드 과량복용 응급치료",
    therapeuticArea: "응급의학 - 오피오이드과량",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Safety/Labeling",
    notes: "변경승인",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208411",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-09",
    ndaBlaNumber: "NDA 211616",
    applicationNo: "211616",
    applicationType: "NDA",
    brandName: "NEXLETOL",
    activeIngredient: "bempedoic acid",
    sponsor: "Esperion Therapeutics",
    indicationFull: "고콜레스테롤혈증 치료",
    therapeuticArea: "심장내과 - 고콜레스테롤",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Efficacy",
    notes: "변경승인. ATP-Citrate Lyase Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211616",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-09",
    ndaBlaNumber: "NDA 211617",
    applicationNo: "211617",
    applicationType: "NDA",
    brandName: "NEXLIZET",
    activeIngredient: "bempedoic acid; ezetimibe",
    sponsor: "Esperion Therapeutics",
    indicationFull: "고콜레스테롤혈증 치료 복합제",
    therapeuticArea: "심장내과 - 고콜레스테롤",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Efficacy",
    notes: "변경승인. ATP-Citrate Lyase Inhibitor",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211617",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-12",
    ndaBlaNumber: "BLA 020367",
    applicationNo: "020367",
    applicationType: "BLA",
    brandName: "CEREZYME",
    activeIngredient: "imiglucerase",
    sponsor: "Genzyme",
    indicationFull: "고셔병 효소 대체 요법",
    therapeuticArea: "내분비내과 - 대사질환",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "변경승인. 희귀의약품",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020367",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-12",
    ndaBlaNumber: "NDA 211241",
    applicationNo: "211241",
    applicationType: "NDA",
    brandName: "ZYCUBO",
    activeIngredient: "copper histidinate",
    sponsor: "Sentynl Therapeutics",
    indicationFull: "Menkes disease 소아 환자의 구리 보충 치료",
    therapeuticArea: "소아과 - 대사질환",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: true,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "ORIG-1 (New Molecular Entity)",
    notes: "신규 분자 실체 (NME). 희귀의약품. Breakthrough Therapy 및 Rare Pediatric Disease 지정",
    fdaUrl: "https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-children-menkes-disease",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-13",
    ndaBlaNumber: "NDA 018735",
    applicationNo: "018735",
    applicationType: "NDA",
    brandName: "ISOVUE 200",
    activeIngredient: "iopamidol",
    sponsor: "Bracco",
    indicationFull: "방사선 조영제",
    therapeuticArea: "영상의학 - 조영제",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "변경승인. X-Ray Contrast Activity",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=018735",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-13",
    ndaBlaNumber: "NDA 020327",
    applicationNo: "020327",
    applicationType: "NDA",
    brandName: "ISOVUE 300",
    activeIngredient: "iopamidol",
    sponsor: "Bracco",
    indicationFull: "방사선 조영제",
    therapeuticArea: "영상의학 - 조영제",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "변경승인. X-Ray Contrast Activity",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020327",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-13",
    ndaBlaNumber: "BLA 761274",
    applicationNo: "761274",
    applicationType: "BLA",
    brandName: "YESAFILI",
    activeIngredient: "aflibercept-jbvf",
    sponsor: "Samsung Bioepis",
    indicationFull: "황반변성, 황반부종, 당뇨망막병증, 근시성 맥락막신생혈관 치료",
    therapeuticArea: "안과 - 황반변성",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "BLA - Biosimilar",
    notes: "Eylea (aflibercept) 바이오시밀러",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761274",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-14",
    ndaBlaNumber: "NDA 021812",
    applicationNo: "021812",
    applicationType: "NDA",
    brandName: "ROGAINE",
    activeIngredient: "minoxidil",
    sponsor: "Kenvue Brands",
    indicationFull: "남성형/여성형 탈모 치료 (국소 도포제)",
    therapeuticArea: "피부과 - 탈모",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "변경승인 (Men's/Women's Rogaine 통합)",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021812",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-14",
    ndaBlaNumber: "NDA 021588",
    applicationNo: "021588",
    applicationType: "NDA",
    brandName: "GLEEVEC",
    activeIngredient: "imatinib mesylate",
    sponsor: "Novartis",
    indicationFull: "만성골수성백혈병 및 위장관기질종양 치료",
    therapeuticArea: "항암제 - 백혈병",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "변경승인. 희귀의약품",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021588",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-14",
    ndaBlaNumber: "BLA 761420",
    applicationNo: "761420",
    applicationType: "BLA",
    brandName: "AVTOZMA",
    activeIngredient: "tocilizumab-asgn",
    sponsor: "Celltrion",
    indicationFull: "류마티스 관절염, 거대세포동맥염, 사이토카인 방출 증후군 등 치료",
    therapeuticArea: "류마티스 - 관절염",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Biosimilar",
    notes: "변경승인. Interleukin 6 Receptor Antagonists",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761420",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-15",
    ndaBlaNumber: "BLA 761027",
    applicationNo: "761027",
    applicationType: "BLA",
    brandName: "FILKRI",
    activeIngredient: "filgrastim-laha",
    sponsor: "Accord BioPharma",
    indicationFull: "화학요법 유발 호중구감소증 치료",
    therapeuticArea: "혈액내과 - 호중구감소증",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "BLA - Biosimilar",
    notes: "Neupogen (filgrastim) 바이오시밀러",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761027",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-15",
    ndaBlaNumber: "BLA 761379",
    applicationNo: "761379",
    applicationType: "BLA",
    brandName: "OTULFI",
    activeIngredient: "ustekinumab-aauz",
    sponsor: "Fresenius Kabi",
    indicationFull: "건선, 건선성 관절염, 크론병, 궤양성 대장염 치료",
    therapeuticArea: "류마티스 - 자가면역질환",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Biosimilar",
    notes: "변경승인. Interleukin-12 Antagonists",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761379",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-15",
    ndaBlaNumber: "NDA 021920",
    applicationNo: "021920",
    applicationType: "NDA",
    brandName: "NAPROXEN SODIUM",
    activeIngredient: "naproxen sodium",
    sponsor: "BionPharma",
    indicationFull: "소염 진통제",
    therapeuticArea: "정형외과 - 진통",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "변경승인",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021920",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-15",
    ndaBlaNumber: "NDA 216774",
    applicationNo: "216774",
    applicationType: "NDA",
    brandName: "ALVAIZ",
    activeIngredient: "cetirizine hydrochloride; pseudoephedrine hydrochloride",
    sponsor: "Teva Pharmaceuticals",
    indicationFull: "알레르기 비염 증상 완화",
    therapeuticArea: "이비인후과 - 알레르기",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Labeling",
    notes: "변경승인",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216774",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-16",
    ndaBlaNumber: "BLA 761269",
    applicationNo: "761269",
    applicationType: "BLA",
    brandName: "LEQEMBI",
    activeIngredient: "lecanemab-irmb",
    sponsor: "Eisai",
    indicationFull: "초기 알츠하이머병 치료",
    therapeuticArea: "신경과 - 알츠하이머",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Efficacy",
    notes: "변경승인. Amyloid Beta-directed Antibody",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761269",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-16",
    ndaBlaNumber: "NDA 021529",
    applicationNo: "021529",
    applicationType: "NDA",
    brandName: "NEXPLANON",
    activeIngredient: "etonogestrel",
    sponsor: "Organon",
    indicationFull: "장기 피임 이식제",
    therapeuticArea: "산부인과 - 피임",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "변경승인",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021529",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-16",
    ndaBlaNumber: "NDA 212849",
    applicationNo: "212849",
    applicationType: "NDA",
    brandName: "RYKINDO",
    activeIngredient: "risperidone",
    sponsor: "Shandong Luye",
    indicationFull: "조현병 및 양극성 장애 치료 서방형 제제",
    therapeuticArea: "정신건강의학과 - 조현병",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "변경승인",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212849",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-17",
    ndaBlaNumber: "NDA 019708",
    applicationNo: "019708",
    applicationType: "NDA",
    brandName: "POTASSIUM CHLORIDE IN SODIUM CHLORIDE",
    activeIngredient: "potassium chloride; sodium chloride",
    sponsor: "B. Braun",
    indicationFull: "전해질 보충 수액",
    therapeuticArea: "응급의학 - 수액",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "변경승인",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019708",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-20",
    ndaBlaNumber: "NDA 022211",
    applicationNo: "022211",
    applicationType: "NDA",
    brandName: "ZIRGAN",
    activeIngredient: "ganciclovir",
    sponsor: "Bausch and Lomb",
    indicationFull: "단순포진 각막염 치료",
    therapeuticArea: "안과 - 각막염",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Manufacturing",
    notes: "변경승인. 희귀의약품. DNA Polymerase Inhibitors",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022211",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-20",
    ndaBlaNumber: "NDA 215866",
    applicationNo: "215866",
    applicationType: "NDA",
    brandName: "MOUNJARO",
    activeIngredient: "tirzepatide",
    sponsor: "Eli Lilly",
    indicationFull: "제2형 당뇨병 치료",
    therapeuticArea: "내분비내과 - 당뇨병",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Efficacy",
    notes: "변경승인. GIP/GLP-1 Receptor Agonist",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215866",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-20",
    ndaBlaNumber: "NDA 217806",
    applicationNo: "217806",
    applicationType: "NDA",
    brandName: "ZEPBOUND",
    activeIngredient: "tirzepatide",
    sponsor: "Eli Lilly",
    indicationFull: "비만 및 과체중 환자의 체중 관리",
    therapeuticArea: "내분비내과 - 비만",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Efficacy",
    notes: "변경승인. GIP/GLP-1 Receptor Agonist",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-21",
    ndaBlaNumber: "BLA 761498",
    applicationNo: "761498",
    applicationType: "BLA",
    brandName: "AVTOZMA SC",
    activeIngredient: "tocilizumab-anoh",
    sponsor: "Celltrion",
    indicationFull: "류마티스 관절염, 거대세포동맥염, 사이토카인 방출 증후군 등 치료",
    therapeuticArea: "류마티스 - 관절염",
    isOncology: false,
    isBiosimilar: true,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "BLA - Biosimilar",
    notes: "Actemra (tocilizumab) 바이오시밀러",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761498",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-21",
    ndaBlaNumber: "NDA 219285",
    applicationNo: "219285",
    applicationType: "NDA",
    brandName: "EVRYSDI",
    activeIngredient: "risdiplam",
    sponsor: "Genentech",
    indicationFull: "척수성 근위축증 치료",
    therapeuticArea: "신경과 - 근위축증",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Efficacy",
    notes: "변경승인. SMN2 Splicing Modifier",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219285",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-26",
    ndaBlaNumber: "NDA 216395",
    applicationNo: "216395",
    applicationType: "NDA",
    brandName: "QUIOFIC",
    activeIngredient: "folic acid",
    sponsor: "CMP Development",
    indicationFull: "엽산 보충을 위한 새로운 제형",
    therapeuticArea: "영양보충 - 비타민",
    isOncology: false,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: false,
    approvalType: "정규승인",
    supplementCategory: "Type 3 - New Dosage Form",
    notes: "새로운 제형 (New Dosage Form) 승인",
    fdaUrl: "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216395",
  },
  {
    approvalMonth: "2026-01",
    approvalDate: "2026-01-27",
    ndaBlaNumber: "BLA 761145",
    applicationNo: "761145",
    applicationType: "BLA",
    brandName: "DARZALEX FASPRO",
    activeIngredient: "daratumumab and hyaluronidase-fihj",
    sponsor: "Janssen Biotech",
    indicationFull: "자가 조혈모세포이식 부적격 신규 진단 다발골수종 성인 환자의 bortezomib, lenalidomide, dexamethasone (VRd) 병용요법",
    therapeuticArea: "항암제 - 다발골수종",
    isOncology: true,
    isBiosimilar: false,
    isNovelDrug: false,
    isOrphanDrug: true,
    approvalType: "정규승인",
    supplementCategory: "SUPPL - Efficacy (New Indication)",
    notes: "변경승인 - 이식 부적격 NDMM VRd 병용요법 적응증 추가",
    fdaUrl: "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly",
  },
];

export const summaryStats = {
  total: 57,
  oncology: 11,
  nonOncology: 46,
  biosimilar: 12,
  novelDrug: 11,
  novelOncology: 0,
  novelNonOncology: 11,
  orphanDrug: 18,
  orphanOncology: 7,
  orphanNonOncology: 11,
};

export const therapeuticAreaData = [
  { name: "다발골수종", value: 2, category: "항암제" },
  { name: "림프종", value: 2, category: "항암제" },
  { name: "전립선암", value: 2, category: "항암제" },
  { name: "폐암", value: 2, category: "항암제" },
  { name: "유방암", value: 1, category: "항암제" },
  { name: "골전이", value: 1, category: "항암제" },
  { name: "백혈병", value: 1, category: "항암제" },
  { name: "대사질환", value: 2, category: "소아과/내분비" },
  { name: "당뇨병", value: 2, category: "내분비내과" },
  { name: "비만", value: 2, category: "내분비내과" },
  { name: "고콜레스테롤", value: 3, category: "심장내과" },
  { name: "관절염/자가면역", value: 5, category: "류마티스" },
  { name: "탈모", value: 3, category: "피부과" },
  { name: "조영제", value: 2, category: "영상의학" },
  { name: "신경과", value: 5, category: "신경과" },
  { name: "안과", value: 2, category: "안과" },
  { name: "호흡기", value: 4, category: "호흡기내과" },
  { name: "혈액내과", value: 3, category: "혈액내과" },
  { name: "기타", value: 13, category: "기타" },
];

export const approvalTypeData = [
  { name: "정규승인", value: 57 },
  { name: "신속승인", value: 0 },
];

export const drugCategoryData = [
  { name: "항암제", value: 11 },
  { name: "비항암제", value: 46 },
];

export const specialDesignations = [
  { name: "희귀의약품", value: 18, percentage: 32 },
  { name: "신약", value: 11, percentage: 19 },
  { name: "바이오시밀러", value: 12, percentage: 21 },
];
